Myriad Genetics, Inc. (MYGN): Price and Financial Metrics

MYGN POWR Grades

• Value is the dimension where MYGN ranks best; there it ranks ahead of 83.84% of US stocks.
• The strongest trend for MYGN is in Growth, which has been heading up over the past 179 days.
• MYGN ranks lowest in Momentum; there it ranks in the 5th percentile.

MYGN Stock Summary

• Price to trailing twelve month operating cash flow for MYGN is currently 114.71, higher than 96.18% of US stocks with positive operating cash flow.
• For MYGN, its debt to operating expenses ratio is greater than that reported by merely 16.49% of US equities we're observing.
• With a year-over-year growth in debt of -68.06%, Myriad Genetics Inc's debt growth rate surpasses only 4.28% of about US stocks.
• If you're looking for stocks that are quantitatively similar to Myriad Genetics Inc, a group of peers worth examining would be MYO, ITI, LPTH, AGRX, and RFIL.
• Visit MYGN's SEC page to see the company's official filings. To visit the company's web site, go to myriad.com.

MYGN Valuation Summary

• MYGN's price/sales ratio is 4.2; this is 10.53% higher than that of the median Healthcare stock.
• MYGN's price/sales ratio has moved down 18.4 over the prior 243 months.
• Over the past 243 months, MYGN's price/earnings ratio has gone up 101.3.

Below are key valuation metrics over time for MYGN.

MYGN Growth Metrics

Its 4 year cash and equivalents growth rate is now at 0.41%.
• Its year over year cash and equivalents growth rate is now at 23.06%.
• Its 2 year cash and equivalents growth rate is now at 24.23%.

MYGN's revenue has moved down $140,000,000 over the prior 34 months.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	690.6	18.2	-27.2
2021-09-30	684.4	13.7	-57.5
2021-06-30	662.3	-6.3	-97.3
2021-03-31	566.1	28.1	-148
2020-12-31	557	-26.9	-223.7
2020-09-30	597.5	-14.4	-194.1

MYGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• MYGN has a Quality Grade of C, ranking ahead of 61.95% of graded US stocks.
• MYGN's asset turnover comes in at 0.476 -- ranking 93rd of 681 Pharmaceutical Products stocks.
• CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN.

The table below shows MYGN's key quality metrics over time.